EGFR and head and neck squamous cell carcinoma: Besides, miR-9 may serve as a valuable biomarker to identify the HNSCC patients who might benefit from RT + CTX (radiotherapy plus the anti-EGFR monoclonal antibody Cetuximab) therapy [24].